Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Karzai, Fatima
Madan, Ravi Amrit
Theoret, Marc Robert
Arlen, Philip M.
Strauss, Julius
Chun, Guinevere
Couvillon, Anna
Harold, Nancy
Chen, Clara
Dawson, Nancy Ann
Apolo, Andrea Borghese
Steinberg, Seth M.
Trepel, Jane B.
Wright, John Joseph
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NCI, Bethesda, MD 20892 USA
[3] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] NCI, Genitourinary Malignancies Branch, NIH, Bethesda, MD 20892 USA
[5] NIH, Dept Nucl Med, Ctr Clin, Bethesda, MD USA
[6] Lombardi Comprehens Canc Ctr, Washington, DC USA
[7] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
[8] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[9] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
[10] NCI, Clin Pharmacol Program, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    Horgan, Anne M.
    Seruga, Bostjan
    Pond, Greg R.
    Alibhai, Shabbir M.
    Amir, Eitan
    De Wit, Ronald
    Eisenberger, Mario A.
    Tannock, Ian F.
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (02) : 119 - 126
  • [22] Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).
    Kohli, Manish
    Huang, Xiaoyi
    Yuan, Tiezheng
    Sun, Zhifu
    Costello, Brian Addis
    Quevedo, Fernando
    Tan, Winston
    Nandy, Debashis
    Longenbach, Sherri
    Wang, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [23] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [24] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    R Petrioli
    A Pascucci
    R Conca
    G Chiriacò
    E Francini
    G Bargagli
    A I Fiaschi
    A Manganelli
    G De Rubertis
    G Barbanti
    R Ponchietti
    G Francini
    British Journal of Cancer, 2011, 104 : 613 - 619
  • [25] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [26] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naive, metastatic, castrate-resistant prostate cancer(CRPC)
    De Souza, P. L.
    Mellado, B.
    Pfister, C.
    Rosenthal, M.
    Castellano, D. E.
    Weber, D.
    Ferrara, S.
    Shaik, N.
    Tan, E.
    Patterson, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    Petrioli, R.
    Pascucci, A.
    Conca, R.
    Chiriaco, G.
    Francini, E.
    Bargagli, G.
    Fiaschi, A. I.
    Manganelli, A.
    De Rubertis, G.
    Barbanti, G.
    Ponchietti, R.
    Francini, G.
    BRITISH JOURNAL OF CANCER, 2011, 104 (04) : 613 - 619
  • [29] Phase II trial of intravenous carboplatin (C), oral everolimus (E), and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trials Consortium study.
    Veeraputhiran, Muthu Kumaran
    Shevrin, Daniel H.
    Stein, Mark N.
    Heilbrun, Lance K.
    Smith, Daryn
    Li, Jing
    Dickow, Brenda
    Heath, Elisabeth I.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] βIII-tubulin expression as a predictor of docetaxel resistance in metastatic castrate-resistant prostate cancer
    Sanchez, Bertha E.
    Gupta, Nilesh
    Mahan, Meredith
    Barrack, Evelyn R.
    Reddy, Prem-veer
    Hwang, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345